Nano-selenium in major depressive disorder

The effect of nano-selenium supplementation on JAK2, STAT3, SRC and indoleamine 2,3-dioxygenase gene expression, serum total antioxidant capacity, serum glutathione peroxidase and malondialdehyde levels, and depressive symptoms in patients with major depressive disorder; A triple-blind randomized controlled trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20091114002709N62

Enrollment

Registered

2023-07-29

Start date

2023-08-22

Completion date

Unknown

Last updated

2023-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Major Depressive Disorder. Major depressive disorder, recurrent

Interventions

Intervention group: Nanoselenium capsule containing 55 micrograms of selenium

Control group: Placebo (corn starch).

Eligibility

Sex/Gender

All

Age

18 Years to 50 Years

Inclusion criteria

Inclusion criteria: Suffering from major depressive disorder based on DSM-V (Structured Clinical Interview for DSM Disorders (SCID)) Being in the age group of 18 to 50 years Not using antidepressants (including sertraline, fluoxetine, citalopram, or amitriptyline) for 3 months or more before the start of the study Body mass index of at least 18.5 kg/m2 and a maximum of 30 kg/m2 Desire to participate in the study and complete the informed consent form based on knowledge and consent to participate in the study

Exclusion criteria

Exclusion criteria: History of autoimmune, neurological, thyroid, cancer, kidney, liver, cardiovascular or respiratory diseases, psychotic and bipolar disorders, neurodegenerative disorders A history of any disease that causes a change in a person’s dietary habits and physical activity High risk of suicide Pregnancy and breastfeeding Taking nutritional supplements such as antioxidant or omega 3 or vitamin D supplements less than 6 weeks before the start of the study alcohol consumption Smoking Following a specific dietary pattern Participating in another study within the past two months

Design outcomes

Primary

Measure	Time frame
SRC gene expression. Timepoint: At the beginning of the study and the twelfth week. Method of measurement: Real-time PCR.;JAK2 gene expression. Timepoint: At the beginning of the study and the twelfth week. Method of measurement: Real-time PCR.;STAT3 gene expression. Timepoint: At the beginning of the study and the twelfth week. Method of measurement: Real-time PCR.;Indoleamine 2 and 3 dioxygenase gene expression. Timepoint: At the beginning of the study and the twelfth week. Method of measurement: Real-time PCR.	—

Measure

Time frame

SRC gene expression. Timepoint: At the beginning of the study and the twelfth week. Method of measurement: Real-time PCR.;JAK2 gene expression. Timepoint: At the beginning of the study and the twelfth week. Method of measurement: Real-time PCR.;STAT3 gene expression. Timepoint: At the beginning of the study and the twelfth week. Method of measurement: Real-time PCR.;Indoleamine 2 and 3 dioxygenase gene expression. Timepoint: At the beginning of the study and the twelfth week. Method of measurement: Real-time PCR.

—

Secondary

Measure	Time frame
Serum total antioxidant capacity. Timepoint: At the beginning of the study and the twelfth week. Method of measurement: Colorimetric.;Serum glutathione peroxidase level. Timepoint: At the beginning of the study and the twelfth week. Method of measurement: Colorimetric.;Serm malondialdehyde level. Timepoint: At the beginning of the study and the twelfth week. Method of measurement: Colorimetric.;Depressive symptoms. Timepoint: At the beginning of the study and the twelfth week. Method of measurement: Hamilton Depression Rating Scale.	—

Measure

Time frame

Serum total antioxidant capacity. Timepoint: At the beginning of the study and the twelfth week. Method of measurement: Colorimetric.;Serum glutathione peroxidase level. Timepoint: At the beginning of the study and the twelfth week. Method of measurement: Colorimetric.;Serm malondialdehyde level. Timepoint: At the beginning of the study and the twelfth week. Method of measurement: Colorimetric.;Depressive symptoms. Timepoint: At the beginning of the study and the twelfth week. Method of measurement: Hamilton Depression Rating Scale.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFarzad shidfar

Iran University of Medical Sciences

farzadshidfar@yahoo.com+98 21 8860 2218

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026